FDA approves Sagent's general anesthetic midazolam

Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA's approval of four presentations of midazolam injection, USP, a general anesthetic.  Sagent expects to launch midazolam, which will be offered in latex-free vials, in 2011.  According to 2010 IMS data, the annual U.S. market for injectable midazolam approximated $52 million.  

"Approval of midazolam marks the ninth FDA approval from our collaboration with Strides Arcolab and is an important addition to our anesthesiology portfolio," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent.  "Each of our anesthesiology products, as well as all of our injectable products, includes Sagent's proprietary PreventIV Measures packaging and labeling designed to help with the reduction of medication errors."

Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 20 injectable products for the U.S. market.  Under the collaboration, Strides is responsible for developing and supplying injectable products that Sagent will market in the United States.

SOURCE Sagent Pharmaceuticals, Inc.